Previous Close | 6.20 |
Open | 6.20 |
Bid | 11.00 |
Ask | 12.70 |
Strike | 19.00 |
Expire Date | 2024-08-16 |
Day's Range | 6.20 - 6.20 |
Contract Range | N/A |
Volume | |
Open Interest | 58 |
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.